HALOZYME THERAPEUTICS INC (HALO)

US40637H1095 - Common Stock

50.27  +0.61 (+1.23%)

After market: 50.27 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (6/18/2024, 7:00:01 PM)

After market: 50.27 0 (0%)

50.27

+0.61 (+1.23%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month35.32%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap6.40B
Shares
PE16.22
Fwd PE9.99
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

HALO Daily chart

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 393 full-time employees. The company went IPO on 2003-01-30. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company’s proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids. The Company’s commercially approved product, Hylenex recombinant (Hylenex), and its ENHANZE partners approved products and product candidates are based on rHuPH20. The company also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that is designed to provide commercial or functional advantages. The company has a commercial portfolio of proprietary products, including XYOSTED, TLANDO and NOCDURNA and partnered commercial products and ongoing product development programs with several pharmaceutical companies.

Company Info

HALOZYME THERAPEUTICS INC

12390 El Camino Real

San Diego CALIFORNIA 92121-1345

P: 18587948889

CEO: Helen I. Torley

Employees: 393

Website: https://www.halozyme.com/

HALO News

ChartMill News Image17 hours ago - ChartmillDon't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.

In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.

News Image4 days ago - InvestorPlaceThe 3 Best Healthcare Stocks to Buy in June 2024

Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on.

News Image6 days ago - Investor's Business DailyNeurocrine Biosciences Stock Tops Milestone Amid New Drug Plans

Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.

News Image7 days ago - Investor's Business DailyMadrigal Pharmaceuticals Stock Earns RS Rating Upgrade

On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.

News Image8 days ago - Investor's Business DailyKrystal Biotech Stock Sees RS Rating Jump To 91

On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88.

News Image12 days ago - Investor's Business DailyHalozyme Therapeutics Scores RS Rating Jump To 91

On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91.

HALO Twits

Here you can normally see the latest stock twits on HALO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example